Medtronic to buy Contego Medical for $380M

Medtronic plans to acquire Contego Medical, a privately held medical device company, for $380 million. The deal will expand Medtronic's carotid disease treatments and is expected to close in Q3 of its fiscal year. Medtronic expects minimal dilution to earnings in fiscal 2027 and 2028, then neutrality or accretion after that.

Original reporting
Published Nov 16, 2026, 3:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medtronic to buy Contego Medical for $380M — source image
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

Medtronic’s acquisition adds carotid revascularization capabilities and complements its Liberant thrombectomy system, with a defined $380M valuation and an EPS impact trajectory through fiscal 2028.

02

Market read

Traders can update MDT’s deal-implied valuation and forward EPS expectations based on the disclosed price, timing, and dilution-to-accretion profile.

03

What to watch

Regulatory and integration timelines for device portfolios, plus reliance on the existing Contego exclusive US distribution agreement, could drive outcomes more than the headline valuation.

Relevance 8/10Novelty 8/10Timing: deal announced Monday, with expected close in Medtronic fiscal Q3

Background

Contego is a privately held device company focused on carotid artery disease and peripheral thrombectomy, including the Neuroguard IEP carotid stent system and Excipio thrombectomy device.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

Medtronic plans to acquire Contego Medical for $380M, expanding carotid disease treatments and targeting completion in fiscal Q3 2027.

Expected impact

Likely modest upside as investors price in portfolio expansion, offset by deal execution and integration uncertainty.

Evidence & confidence

The article discloses a specific $380M acquisition, timing (fiscal Q3), and EPS impact profile, which are direct inputs to near-term valuation and risk assessment.

Market effects

Reinforces consolidation in neurovascular and peripheral vascular device markets, potentially increasing competitive focus on carotid revascularization platforms.

Limited direct regional read-through; primarily US-focused distribution and device commercialization.

Could modestly affect global medtech M&A expectations in vascular intervention, but impact is company-specific.

Counterpoint

The stated “minimally dilutive” and later accretion may still be optimistic if Contego’s clinical adoption or reimbursement dynamics lag expectations.

Key entities

  • Medtronic

    Plans to buy Contego Medical for $380M and expand its carotid disease and thrombectomy portfolio.

  • Contego Medical

    Privately held neurovascular and peripheral thrombectomy device company with Neuroguard IEP and Excipio products.

  • David Moeller

    Medtronic SVP and president of Peripheral Vascular Health, quoted on the strategic rationale.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.